Clinically reviewed by Dr. Sarah Boss, MD
A seizure, collapse, severe breathing difficulty or sudden major change in awareness requires urgent assessment. Have combinations with amantadine, ketamine or dextromethorphan checked before use. Liquid pumps and concentrations are product-specific; do not restart after several missed days or change formulations independently.
Memantine is used to manage symptoms of Alzheimer’s dementia in appropriate stages and circumstances. It works differently from medicines such as donepezil, rivastigmine and galantamine, and is sometimes prescribed alongside an acetylcholinesterase inhibitor. It is not a cure, a general memory enhancer or an established detox medicine. A useful plan identifies the diagnosis, the actual formulation and the goals that matter to the person receiving treatment.
What memantine is used for
Memantine is an NMDA receptor antagonist that modifies the effects of glutamate signaling. It is used for symptomatic treatment of moderate to severe Alzheimer’s dementia under the relevant product authorization. The medicine may help aspects of thinking, behavior or daily functioning, but response varies and the underlying disease can continue to progress. [1]
Ask the clinician to explain why memantine is appropriate now. A prescription may reflect the stage of illness, intolerance of another medicine or a decision to add treatment, not simply a belief that a higher number of tablets is better. Record the intended benefit so later reviews can assess more than whether the prescription has been renewed.
How it fits with other dementia medicines
NICE recommends memantine in specified Alzheimer’s-treatment situations and discusses adding it to an acetylcholinesterase inhibitor as disease severity changes. It also considers memantine in dementia with Lewy bodies when those inhibitors are not tolerated or are contraindicated. These recommendations do not establish that memantine treats every dementia subtype or every cognitive complaint. [2]
Clarify whether an existing donepezil, rivastigmine or galantamine prescription continues. Do not assume that a new medicine automatically replaces the earlier one, or that both should continue because both remain at home. A pharmacist can reconcile the actual packages with the written plan.
NMDA activity does not make it ketamine
Memantine, ketamine and dextromethorphan have activity at NMDA-related pathways, but they are not interchangeable treatments. Differences in pharmacology, evidence and product authorization matter. A shared receptor term does not show that memantine is an approved antidepressant, a substitute for ketamine treatment or a safe way to reproduce another medicine’s subjective effects.
If an off-label psychiatric use is proposed, ask which evidence supports that specific diagnosis, what uncertainty remains and how benefit will be measured. The fact that a medicine has been studied in another condition should not be presented as proof of established routine use. An informed discussion should include alternatives and a clear plan for review.
Formulations, brands and combination products
Memantine is available in standard or dispersible tablets, oral solutions and, in some markets, extended-release capsules. Products have different instructions and local availability. MedlinePlus identifies Namenda and Namenda XR as no longer marketed US brands, while generics may remain available. Namzaric is a distinct combination with donepezil, not memantine alone. [3]
Read both ingredients when a combination product is used. Do not add separate donepezil or memantine to it without explicit instructions. A change of brand or release system should be checked against the prescription rather than managed by matching tablet size or the number printed on the box.
Liquid pumps and measuring errors
Some memantine liquids use a metered pump, while others use a measured oral volume. The amount delivered per pump or milliliter is specific to the product. Follow its preparation and administration instructions, and do not pour an estimated amount or assume a pump from another bottle delivers the same dose. [4]
Ask the pharmacist to demonstrate the device and explain what to do if it appears not to work. Caregivers should use one current record and not repeat an uncertain administration automatically. Keep the bottle in its original packaging and hand over the device instructions when someone else takes responsibility for medicines.
Common effects and practical monitoring
Dizziness, headache, constipation, confusion and sleepiness can occur. Report effects that interfere with walking, eating, engagement or ordinary care. A new symptom should be considered alongside illness, hydration, other medicines and recent changes rather than automatically attributed to dementia progression. Do not drive or undertake hazardous tasks while impaired. [3]
Record concrete observations: a new fall, sleeping through meals, constipation that causes discomfort or a change in participation. A caregiver’s account can be valuable when the person cannot reliably recall events, but it should complement rather than replace the person’s own experience.
Kidney function and changes in elimination
Memantine is cleared largely through the kidneys, and reduced kidney function can require a different prescribing approach. Conditions or products that make urine more alkaline can also reduce elimination. Product information highlights major dietary changes, alkalinizing preparations and certain urinary conditions as reasons for monitoring. Do not use this information to manipulate the medicine’s effect yourself. [1]
Tell the clinician about kidney disease, a recent urinary infection and substantial changes in other medical care. Bring relevant test results when services do not share records. A prescription that was suitable before an acute illness may need review afterward, but changes should be coordinated rather than improvised by a caregiver.
Important medicine interactions
Concomitant use with amantadine, ketamine or dextromethorphan should be avoided or reviewed according to the product guidance because of overlapping NMDA effects and the possibility of increased central nervous system reactions. Dextromethorphan can be hidden in a cough remedy. Other medicines may also be relevant, including treatments used in Parkinson’s disease. [4]
Give the pharmacist the full list, including occasional cold and sleep products. Do not stop a neurological medicine independently after reading a warning. Ask the clinicians to agree the safest plan and explain which symptoms should prompt urgent contact. The interaction-review guide can help organize the information.
Mental health symptoms and behavior
Depression, anxiety, hallucinations, agitation and sleep problems may occur in people with dementia, but memantine is not a general acute calming medicine. NICE recommends assessing causes of distress, including pain, delirium and environmental factors. Treatment should be linked to the actual problem rather than using one cognition prescription to explain or manage every change in behavior. [2]
Describe when a difficulty occurs and what seems to precede it. Noise, unfamiliar care, poor sleep or physical discomfort may be relevant. Ask how psychological and environmental support will continue alongside medicines. A person’s distress should not be judged only by how much it disrupts other people.
Alcohol-related cognitive problems are a separate assessment
Memantine is not a routine treatment for alcohol withdrawal, and an NMDA mechanism does not establish that it prevents withdrawal complications. Cognitive symptoms associated with alcohol exposure, malnutrition or acute illness require evaluation. Suspected Wernicke’s encephalopathy needs urgent care and appropriate thiamine treatment rather than a trial of memantine. [5]
For longer-term difficulties, bring the history of alcohol and other substances, injuries, nutrition, mood and sleep. Rehabilitation and addiction treatment may be needed alongside a memory assessment. Avoid assuming that all cognitive impairment has the same cause or the same medication evidence.
Stopping, missed treatment and dependence
Memantine is not ordinarily considered an addictive intoxicant. A change in functioning after stopping should not automatically be called addiction withdrawal. It may reflect loss of symptomatic benefit, another illness or changes in care. After several missed days, consult the prescriber before resuming the previous regimen because reintroduction may need adjustment. [3]
When stopping is considered, ask how the result will be observed and who will review it. Avoid an unrecorded experiment in which several treatments and routines change simultaneously. A planned approach makes it easier to interpret whether comfort, function or adverse effects have improved or worsened.
Urgent symptoms and medical review
A seizure, collapse, severe breathing difficulty or a sudden major change in awareness needs urgent assessment. Acute confusion should not be assumed to be normal dementia progression. Tell emergency staff about the actual memantine product, recent doses and other medicines, including whether an extra dose or a liquid error may have occurred.
Keep emergency guidance distinct from routine concerns. A person who is acutely unwell should not wait for a memory-clinic appointment. On the other hand, persistent constipation, dizziness or reduced engagement should also be discussed rather than allowed to accumulate until the treatment becomes difficult to manage.
Evaluating benefit fairly
Choose a few meaningful goals with the person and their supporters. These may include conversation, familiar routines, comfort during care or participation in activities. Cognitive tests can contribute, but language, education, sensory difficulties and illness affect interpretation. NICE advises using an appropriate assessment rather than relying on a score alone when it is unsuitable. [2]
Bring examples of benefit and burden to the appointment. Stability may matter, but it should not be attributed automatically to a medicine without considering other changes. Ask the clinician to explain the reasons for continuing or changing treatment and acknowledge where the effect is uncertain.
Coordinating care and supporting choice
Make responsibilities explicit: who orders the next supply, checks the administration record, arranges tests and reviews symptoms. Involve the person in decisions as much as possible, using accessible explanations and enough time. If capacity is impaired, appropriate clinical and legal decision-making processes are needed rather than informal changes made without consultation.
A handover should include the diagnosis, treatment purpose, exact formulation, recent interruptions and concerns about tolerability. The medication-review checklist can help prepare that information. Safe administration and person-centered support remain necessary even when the prescription itself is unchanged.
Frequently asked questions
Is memantine stronger than donepezil?
That is not a useful simple ranking. They work differently and have different roles in treatment pathways. Ask why one or both are appropriate for the current diagnosis and stage.
Can it replace ketamine or an antidepressant?
No. A shared receptor term does not establish equivalent effects, evidence or dosing. Any off-label proposal needs a specific clinical rationale and monitoring plan.
Does a combination capsule contain only memantine?
Not necessarily. Namzaric also contains donepezil. Check active ingredients and do not duplicate either component with an old prescription.
